Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
10:40am, Thursday, 22'nd Aug 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
05:03am, Thursday, 22'nd Aug 2024
Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai and Biogen's new Leqembi drug, after it was approved by the country's regulator but deemed too expensive f
Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark
09:43am, Saturday, 17'th Aug 2024
Biogen's Q2 earnings show flat revenue growth but a 31% increase in non-GAAP EPS. The focus is on Alzheimer's drug Leqembi as potential revenue driver, now it has secured full FDA approval and is gene
Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs
01:14pm, Tuesday, 13'th Aug 2024
Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.
OpenFold AI Research Consortium Welcomes Six New Members: Astex, Biogen, Congruence, Polaris Quantum, Psivant, and SandboxAQ
05:30am, Tuesday, 13'th Aug 2024
DAVIS, Calif.--(BUSINESS WIRE)--The non-profit consortium is developing publicly accessible advanced AI-based drug discovery software tools.
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
09:05am, Sunday, 11'th Aug 2024
A blood test that checks for an abnormal protein could detect 90% of Alzheimer's cases. Eli Lilly recently obtained approval for an early Alzheimer's treatment, Kisunla.
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
10:41am, Friday, 02'nd Aug 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
01:25pm, Thursday, 01'st Aug 2024
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
12:55pm, Thursday, 01'st Aug 2024
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 01'st Aug 2024
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to
Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates
09:05am, Thursday, 01'st Aug 2024
Biogen Inc. (BIIB) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $4 per share. This compares to earnings of $4.02 per share a year ago.
Drug maker Biogen boosts profit outlook and tops Q2 profit estimate
07:19am, Thursday, 01'st Aug 2024
Biogen Inc.'s stock BIIB rose 1.8% in premarket trading on Thursday after the drug aker boosted its outlook for its adjusted 2024 profit and topped Wall Street's second-quarter profit expectations. Th
Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction
06:56am, Thursday, 01'st Aug 2024
Biogen reported second-quarter earnings and revenye that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug, Leqem
Biogen lifts 2024 profit forecast on hopes of new product launches
06:50am, Thursday, 01'st Aug 2024
Biogen lifted its full-year earnings forecast on Thursday, as the launch of new treatments such as rare disease drug Skyclarys is expected to make up for a market-share loss of its older multiple scle
Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therapeutics to the cerebrospinal fluid (CSF). The first stage of the pivotal IDE PI
